Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 29, 2021 - Issue 7-8
Submit an article Journal homepage
302
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy

Aina Moll-Udinaa Department of Ophthalmology, Ophthalmology Clinic Institute, Hospital Clinic, University of Barcelona, Barcelona, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4753-2111
, MDORCID Icon,
Lucía Miguel Escudera Department of Ophthalmology, Ophthalmology Clinic Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain
, MD,
Inés Hernanza Department of Ophthalmology, Ophthalmology Clinic Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain
, MD,
Victor Llorença Department of Ophthalmology, Ophthalmology Clinic Institute, Hospital Clinic, University of Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-7375-1564
, MD, PhDORCID Icon,
Alex Fonollosab Department of Ophthalmology, BioCruces Health Research Institute, Cruces Hospital, University of Basque Country, Leioa, Spain
, MD, PhD,
Miguel Cordero Comac Department of Ophthalmology, University Hospital of León, IBIOMED, University of León, León, Spain
, MD, PhD,
Maite Sainz de la Mazaa Department of Ophthalmology, Ophthalmology Clinic Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain
, MD, PhD,
Gerard Espinosad Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0003-1336-0163
, MD, PhDORCID Icon,
J. Jacobo González Guijarroe Department of Ophthalmology, University Hospital of La Princesa, Madrid, Spain
, MD, PhD,
Fernando Lopez Lopezf Department of Ophthalmology, Santiago Hospital, Santiago de Compostela, Spain
, MD, PhD,
Carmen Alba-Linerog Department of Ophthalmology, Regional University Hospital of Málaga, University of Malaga, Málaga, SpainORCID Iconhttps://orcid.org/0000-0002-1399-5380
, MD, PhDORCID Icon,
Marisa Hernándezh Department of Ophthalmology, General Hospital of Valencia, Valencia, Spain
, MD,
Lucía Martínez Costai Department of Ophthalmology, University Dr. Peset Hospital, Valencia, Spain
, MD,
Diego Celdrán Vivancose Department of Ophthalmology, University Hospital of La Princesa, Madrid, Spain
, MD,
Lena Giraltb Department of Ophthalmology, BioCruces Health Research Institute, Cruces Hospital, University of Basque Country, Leioa, Spain
, MD,
Joseba Artarazb Department of Ophthalmology, BioCruces Health Research Institute, Cruces Hospital, University of Basque Country, Leioa, Spain
, MD, PhD,
Pablo Soler Bartrinaj Department of Ophthalmology, Bierzo Hospital, León, Spain
, MD,
Margarita Jódar Márquezg Department of Ophthalmology, Regional University Hospital of Málaga, University of Malaga, Málaga, Spain
, MD, PhD,
Rosario García de Vicuñak Department of Rheumatology, University Hospital of La Princesa, Madrid, SpainORCID Iconhttps://orcid.org/0000-0001-9096-3780
, MDORCID Icon,
Cristina Esquinasl Vall Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain
&
Alfredo Adána Department of Ophthalmology, Ophthalmology Clinic Institute, Hospital Clinic, University of Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-0849-8814
, MD, PhDORCID Icon show all
Pages 1591-1598 | Received 30 Jan 2020, Accepted 11 May 2020, Published online: 13 Jul 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

Purpose: To assess the efficacy and safety of adalimumab in elderly patients with noninfectious uveitis (NIU).

Methods: An observational, retrospective, multicenter study was done. Changes in best-corrected visual acuity (BCVA), inflammatory activity parameters, central retinal thickness (CRT), and the occurrence of adverse events (AE) developed during follow-up were recorded.

Results: A total of 82 eyes from 41 patients 60 years of age and older with noninfectious uveitis treated with adalimumab were included. A significant improvement in BCVA (71.5 to 75.4 letters, p = .001) and in CRT (311.1 μm to 265 μm, p = .001) was observed. Moreover, a significant decrease from baseline in the rate of patients with anterior chamber cell (ACC) >0+ (34.6% to 5.7%, p = <0.001) or vitreous haze>0+ (21.3% to 4.3%, p = .002) was determined. AEs were observed in 11 patients (26.8%).

Conclusion: Adalimumab can be safe and efficacious for the treatment of NIU in patients 60 years of age and older.

Declaration of interest

No competing financial interests exist.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 815.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.